Skip to content

Slowing CD4 cell decline with IL-2 allows HIV treatment to be deferred by 92 weeks

Efavirenz superior to lopinavir/ritonavir in very advanced HIV, Mexican trial shows

Raltegravir versus efavirenz in treatment-naïves at 96 weeks: continued efficacy and fewer adverse effects

Treatment outcomes in Latin America, China and Botswana: successes and shortfalls

Widespread NRTI and NNRTI resistance seen in Malawian patients failing first-line antiretroviral therapy

Circumcision will halve HIV rates but may take decades to reach full impact

Swiss statement that ‘undetectable equals uninfectious’ creates more controversy in Mexico City

HIV programme in Western Kenya successfully delivers isoniazid preventive therapy to thousands

Who defines ‘Positive prevention’?